167 related articles for article (PubMed ID: 23337026)
41. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
[TBL] [Abstract][Full Text] [Related]
42. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
[TBL] [Abstract][Full Text] [Related]
44. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
Jia XL; Chen G
Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
[TBL] [Abstract][Full Text] [Related]
45. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
46. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
47. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
[TBL] [Abstract][Full Text] [Related]
48. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
[TBL] [Abstract][Full Text] [Related]
49. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
50. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.
Ayyoub M; Memeo L; Alvarez-Fernández E; Colarossi C; Costanzo R; Aiello E; Martinetti D; Valmori D
Cancer Immunol Res; 2014 Oct; 2(10):943-8. PubMed ID: 24866168
[TBL] [Abstract][Full Text] [Related]
51. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
[TBL] [Abstract][Full Text] [Related]
52. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
53. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2013 Jul; 81(1):53-9. PubMed ID: 23632273
[TBL] [Abstract][Full Text] [Related]
54. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
[TBL] [Abstract][Full Text] [Related]
57. The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma.
Clay TD; Do H; Sundararajan V; Moore MM; Conron M; Wright GM; McLachlan SA; Dobrovic A; Russell PA
J Thorac Oncol; 2014 May; 9(5):654-63. PubMed ID: 24722155
[TBL] [Abstract][Full Text] [Related]
58. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study.
Malapelle U; de Rosa N; Rocco D; Bellevicine C; Crispino C; Illiano A; Piantedosi FV; Nappi O; Troncone G
J Clin Pathol; 2012 Jan; 65(1):87-91. PubMed ID: 21945923
[TBL] [Abstract][Full Text] [Related]
59. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma.
Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC
Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419
[TBL] [Abstract][Full Text] [Related]
60. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
